Becton, Dickinson and Company (NYSE:BDX) Stock Price Expected to Rise, Evercore Analyst Says

Becton, Dickinson and Company (NYSE:BDX) had its price objective raised by analysts at Evercore from $180.00 to $190.00 in a report released on Thursday,MarketScreener reports. Evercore’s target price suggests a potential upside of 23.07% from the stock’s current price.

Several other brokerages have also issued reports on BDX. Barclays initiated coverage on shares of Becton, Dickinson and Company in a research report on Tuesday, February 10th. They set an “overweight” rating and a $202.00 target price for the company. Royal Bank Of Canada set a $175.00 price target on shares of Becton, Dickinson and Company in a research note on Tuesday, April 14th. Stifel Nicolaus upped their price objective on Becton, Dickinson and Company from $210.00 to $215.00 and gave the stock a “buy” rating in a research note on Wednesday, January 7th. The Goldman Sachs Group initiated coverage on Becton, Dickinson and Company in a report on Friday, April 10th. They issued a “neutral” rating and a $167.00 target price on the stock. Finally, Piper Sandler lowered their target price on Becton, Dickinson and Company from $170.00 to $159.00 and set a “neutral” rating on the stock in a research report on Friday, April 17th. Seven research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $184.71.

Becton, Dickinson and Company Stock Up 6.6%

BDX stock opened at $154.38 on Thursday. Becton, Dickinson and Company has a fifty-two week low of $127.59 and a fifty-two week high of $187.35. The business’s 50-day moving average is $158.49 and its two-hundred day moving average is $181.08. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.58 and a current ratio of 1.05. The company has a market cap of $43.96 billion, a price-to-earnings ratio of 24.93, a P/E/G ratio of 10.32 and a beta of 0.22.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings results on Thursday, May 7th. The medical instruments supplier reported $2.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.77 by $0.13. Becton, Dickinson and Company had a return on equity of 15.76% and a net margin of 8.01%.The business had revenue of $4.71 billion during the quarter, compared to the consensus estimate of $4.67 billion. During the same period in the previous year, the company posted $3.35 EPS. The business’s quarterly revenue was up 5.2% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. As a group, analysts forecast that Becton, Dickinson and Company will post 12.53 earnings per share for the current year.

Becton, Dickinson and Company announced that its Board of Directors has initiated a share buyback program on Tuesday, January 27th that permits the company to repurchase $10.00 million in shares. This repurchase authorization permits the medical instruments supplier to repurchase up to 0% of its shares through open market purchases. Shares repurchase programs are typically an indication that the company’s board of directors believes its stock is undervalued.

Insider Activity at Becton, Dickinson and Company

In other news, Director Bertram L. Scott sold 953 shares of the firm’s stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $182.61, for a total transaction of $174,027.33. Following the sale, the director directly owned 36,763 shares in the company, valued at $6,713,291.43. This trade represents a 2.53% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In the last 90 days, insiders have sold 1,102 shares of company stock worth $198,909. 0.40% of the stock is owned by company insiders.

Institutional Investors Weigh In On Becton, Dickinson and Company

Institutional investors and hedge funds have recently bought and sold shares of the business. Activest Wealth Management boosted its stake in shares of Becton, Dickinson and Company by 285.3% in the third quarter. Activest Wealth Management now owns 131 shares of the medical instruments supplier’s stock worth $25,000 after acquiring an additional 97 shares during the period. Imprint Wealth LLC bought a new stake in Becton, Dickinson and Company during the 3rd quarter valued at approximately $25,000. Steph & Co. raised its stake in Becton, Dickinson and Company by 95.6% during the 4th quarter. Steph & Co. now owns 133 shares of the medical instruments supplier’s stock valued at $26,000 after purchasing an additional 65 shares during the period. SHP Wealth Management purchased a new position in Becton, Dickinson and Company in the 4th quarter worth approximately $26,000. Finally, Meeder Asset Management Inc. lifted its holdings in Becton, Dickinson and Company by 152.2% in the 1st quarter. Meeder Asset Management Inc. now owns 169 shares of the medical instruments supplier’s stock worth $27,000 after purchasing an additional 102 shares in the last quarter. 86.97% of the stock is owned by institutional investors.

More Becton, Dickinson and Company News

Here are the key news stories impacting Becton, Dickinson and Company this week:

• Positive Sentiment: Q2 results beat analyst expectations — adjusted EPS of $2.90 vs. $2.77 consensus and revenue of $4.71B vs. $4.67B, driven by broad segment strength and improved margins. BD Reports Second Quarter Fiscal 2026 Financial Results
• Positive Sentiment: Company raised full‑year adjusted EPS guidance to $12.52–$12.72 (slightly above consensus) and raised its annual profit forecast, citing strength in drug‑delivery devices and surgical equipment — a key driver of the rally. Becton Dickinson raises annual profit forecast on strength in drug delivery devices
• Positive Sentiment: Significant capital allocation moves: executed a $2.0B accelerated share repurchase (ASR) and retired $2.1B of debt in the quarter — supports EPS per share and reduces leverage. BD Reports Second Quarter Fiscal 2026 Financial Results
• Positive Sentiment: Management change announced — Vitor Roque named CFO effective May 7, providing leadership clarity after the quarter. BD Appoints Vitor Roque Chief Financial Officer
• Neutral Sentiment: Company reaffirmed low‑single‑digit revenue growth for FY‑2026 — indicates modest top‑line expansion even as margins and EPS outlook improve. BD forecasts FY 2026 adjusted EPS of $12.52-$12.72 while reaffirming low-single-digit revenue growth
• Neutral Sentiment: Options flow shows elevated activity that some services interpret as bets on near‑term volatility or a price move — worth watching but not a fundamental driver yet. Is the Options Market Predicting a Spike in Becton Dickinson Stock?
• Negative Sentiment: GAAP EPS and adjusted EPS remain lower year‑over‑year (prior-year EPS was $3.35 vs. $2.90 this quarter), signaling some profit pressure despite the beat — a caution for longer‑term growth expectations. Becton, Dickinson and Company earnings report

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.